– Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients – – Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than …
Read More »
Breaking News
- MD Pharma’s UVeCARE Celebrates Major Win at Natural Health Awards 2025
- Greenbriar Announces Closing of Non-Brokered Private Placement and Completion of Shares for Debt Transaction
- Renegade Gold Announces Closing of Debt Settlement
- Barksdale Announces Repricing of Crescat Private Placement
- ION Closes Upsized Non-Brokered Private Placement
- Comprehensive Healthcare Systems Announces Extension of Second Tranche of Private Placement
- Planet Ventures Announces Strategic Investment in GRU Space to Support First Hotel On the Moon; Announces Repayment of Convertible Debentures
- Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering
- Highway 50 Gold Completes Upsized Non-Brokered Private Placement of Units
- American Aires Inc. Files Legal Proceedings Against Former Executive
Matribhumi Samachar
Address : 125 - Rajiv Nagar, Vinayakpur, Kanpur - 208025
Mo. No.: 8303063085
Email: [email protected]
Managed By Y2KSOLUTION
Copyright © Matribhumi Samachar